Nivolumab + ipilimumab + trabectedin for sarcoma

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 1 trial. Early trial in people, checking safety. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 13 Apr 2017: Trial started, NCT03138161
  2. 3 May 2017: Trial registered, NCT03138161

The trials

NCT03138161: SAINT:Trabectedin, Ipilimumab and Nivolumab for Previously Treated Advanced Soft Tissue Sarcoma

State
Under way
Phase
Phase 1 and Phase 2
People
250 planned
Started
13 Apr 2017
Primary completion
31 Dec 2030
Arms
Phase 1
Results
None posted
  1. 13 Apr 2017: Trial started
  2. 3 May 2017: Trial registered

How the status changed

  1. 19 Nov 2026: First set: Phase 1 trial

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.